Research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
NASDAQ PULM opened at $2.07 on Friday. The stock has a market capitalization of $7.55 million, a P/E ratio of -0.78 and a beta of 0.99. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $2.75. The stock has a fifty day moving average of $2.07 and a 200-day moving average of $2.03.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The firm had revenue of $1.55 million during the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Technology Stocks Explained: Here’s What to Know About Tech
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
